A Von Deimling
Overview
Explore the profile of A Von Deimling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
162
Citations
4528
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thrombus or tumor? A case report of a rare sarcoma entity: intimal sarcoma of the pulmonary arteries
Dorr A, Florcken A, Bullinger L, Capper D, Deimling A, Kaul D, et al.
Mol Biol Rep
. 2024 Apr;
51(1):568.
PMID: 38656400
Background: Tumor embolism is a very rare primary manifestation of cancers and the diagnosis is challenging, especially if located in the pulmonary arteries, where it can mimic nonmalignant pulmonary embolism....
2.
Dao Trong P, Gluszak M, Reuss D, Deimling A, Wick A, Konig L, et al.
J Neurooncol
. 2023 Jan;
161(3):605-615.
PMID: 36648586
Purpose: Lower-grade glioma (LGG) is rare among patients above the age of 60 ("elderly"). Previous studies reported poor outcome, likely due to the inclusion of isocitrate dehydrogenase (IDH) wildtype astrocytomas...
3.
Livingstone E, Zaremba A, Horn S, Ugurel S, Casalini B, Schlaak M, et al.
Br J Dermatol
. 2020 Feb;
183(5):928-939.
PMID: 32064597
Background: GNAQ and GNA11 mutant nonuveal melanoma represent a poorly characterized rare subgroup of melanoma with a gene mutation profile similar to uveal melanoma. Objectives: To characterize these tumours in...
4.
Deng M, Sill M, Sturm D, Stichel D, Witt H, Ecker J, et al.
Neuropathol Appl Neurobiol
. 2019 Dec;
46(5):422-430.
PMID: 31867747
Aims: DNA methylation-based central nervous system (CNS) tumour classification has identified numerous molecularly distinct tumour types, and clinically relevant subgroups among known CNS tumour entities that were previously thought to...
5.
Feller C, Felix M, Weiss T, Herold-Mende C, Zhang F, Kockmann T, et al.
Acta Neuropathol
. 2019 Nov;
139(1):211-213.
PMID: 31773240
No abstract available.
6.
Korshunov A, Casalini B, Chavez L, Hielscher T, Sill M, Ryzhova M, et al.
Neuropathol Appl Neurobiol
. 2018 Oct;
45(2):108-118.
PMID: 30326163
Aims: Mutations of isocitrate dehydrogenase (IDH)1/2 affect almost all astrocytomas of WHO grade II and III. A subset of IDH-mutant astrocytic tumours progresses to IDH-mutant glioblastoma or presents with the...
7.
Wirsching H, Tabatabai G, Roelcke U, Hottinger A, Jorger F, Schmid A, et al.
Ann Oncol
. 2018 Apr;
29(6):1423-1430.
PMID: 29648580
Background: The addition of bevacizumab to temozolomide-based chemoradiotherapy (TMZ/RT → TMZ) did not prolong overall survival (OS) in patients with newly diagnosed glioblastoma in phase III trials. Elderly and frail...
8.
Gao Y, Weenink B, van den Bent M, Erdem-Eraslan L, Kros J, Sillevis Smitt P, et al.
Eur J Cancer
. 2018 Mar;
94:168-178.
PMID: 29571083
Introduction: The European Organisation for Research and Treatment of Cancer (EORTC) 22033-26033 clinical trial (NCT00182819) investigated whether initial temozolomide (TMZ) chemotherapy confers survival advantage compared with radiotherapy (RT) in low-grade...
9.
Catanzaro G, Besharat Z, Miele E, Chiacchiarini M, Po A, Carai A, et al.
Neuropathol Appl Neurobiol
. 2018 Feb;
44(7):687-706.
PMID: 29478280
Aims: Paediatric low-grade gliomas (pLGGs) are a heterogeneous group of brain tumours associated with a high overall survival: however, they are prone to recur and supratentorial lesions are difficult to...
10.
Chaturvedi A, Herbst L, Pusch S, Klett L, Goparaju R, Stichel D, et al.
Leukemia
. 2017 Feb;
31(10):2020-2028.
PMID: 28232670
Neomorphic mutations in isocitrate dehydrogenase 1 (IDH1) are frequently found in several human cancer types including acute myeloid leukemia (AML) and lead to the production of high levels of the...